Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Completed · Phase 3 · NCT02260986
Conditions: Atopic Dermatitis
At a glance
- Research payments reported, 2025
- $750
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 740
About the trial
- Sponsor
- Regeneron Pharmaceuticals (with Sanofi)
- Tested
- Dupilumab (drug), Placebo (for Dupilumab) (drug), Topical Corticosteroid (TCS) (other)
- Dates
- Started 2014-09; completion 2016-10
- Results posted
- Yes
The primary objective of the study was to demonstrate the efficacy of Dupilumab administered concomitantly with topical corticosteroid (TCS) through Week 16 in adult participants with moderate-to-severe atopic dermatitis (AD) compared to placebo administered concomitantly with TCS.
From ClinicalTrials.gov, last updated 2017-10-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $750 in research payments for this study in 2025 (2 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.